Perspective Therapeutics (NYSEAMERICAN:CATX) Stock Rating Reaffirmed as Buy by BTIG Research

Perspective Therapeutics (NYSEAMERICAN:CATX)‘s stock had its “buy” rating reissued by stock analysts at BTIG Research in a research note issued to investors on Wednesday, Benzinga reports. They currently have a $14.00 price objective on the stock. BTIG Research’s target price would suggest a potential upside of 416.61% from the company’s previous close.

Several other brokerages have also commented on CATX. Wedbush reissued an “outperform” rating and set a $11.00 price objective on shares of Perspective Therapeutics in a report on Tuesday, September 15th. Bank of America dropped their target price on shares of Perspective Therapeutics from $6.00 to $5.00 and set a “neutral” rating for the company in a research report on Friday, August 14th. BMO Capital Markets set a $11.00 price target on shares of Perspective Therapeutics and gave the stock an “outperform” rating in a research note on Tuesday, August 18th. William Blair assumed coverage on shares of Perspective Therapeutics in a report on Friday, September 18th. They issued an “outperform” rating on the stock. Finally, Piper Sandler lowered their price objective on shares of Perspective Therapeutics from $16.00 to $14.00 and set an “overweight” rating on the stock in a research report on Tuesday, August 11th. One investment analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating and one has given a Hold rating to the company’s stock. According to data from MarketBeat.com, Perspective Therapeutics currently has a consensus rating of “Buy” and an average target price of $11.50.

Perspective Therapeutics Price Performance

NYSEAMERICAN:CATX opened at $2.71 on Wednesday. Perspective Therapeutics has a 52-week low of $1.96 and a 52-week high of $6.16. The stock has a fifty day moving average of $2.95 and a 200 day moving average of $3.40.

Perspective Therapeutics (NYSEAMERICAN:CATX) last announced its earnings results on Monday, August 10th. The company reported ($0.22) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.25) by $0.03. Perspective Therapeutics had a negative return on equity of 41.92% and a negative net margin of 28,467.97%.The business had revenue of $0.08 million for the quarter, compared to analyst estimates of $0.09 million. Equities analysts predict that Perspective Therapeutics will post -0.98 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Perspective Therapeutics

A number of hedge funds have recently made changes to their positions in CATX. Commodore Capital LP purchased a new stake in Perspective Therapeutics during the first quarter valued at about $26,424,000. Affinity Asset Advisors LLC increased its stake in Perspective Therapeutics by 954.9% in the 1st quarter. Affinity Asset Advisors LLC now owns 3,164,582 shares of the company’s stock worth $13,196,000 after purchasing an additional 2,864,582 shares during the period. Avidity Partners Management LP boosted its stake in shares of Perspective Therapeutics by 88.4% during the first quarter. Avidity Partners Management LP now owns 6,049,999 shares of the company’s stock valued at $25,228,000 after purchasing an additional 2,839,266 shares during the period. Spruce Street Capital LP bought a new position in shares of Perspective Therapeutics in the first quarter worth approximately $10,955,000. Finally, Yu Fan bought a new position in shares of Perspective Therapeutics in the first quarter worth approximately $4,401,000. 54.66% of the stock is currently owned by institutional investors.

Key Perspective Therapeutics News

Here are the key news stories impacting Perspective Therapeutics this week:

• Positive Sentiment: FDA grants Fast Track designation for PSV359. The designation supports expedited development and review of PSV359 for adults with advanced, unresectable or metastatic FAP-positive solitary fibrous tumors, a rare cancer with limited treatment options. It may enable more frequent FDA interactions and, if additional requirements are met, rolling review, Accelerated Approval or Priority Review. Early imaging data showed strong tumor uptake and rapid renal clearance. FDA Fast Track designation announcement
• Positive Sentiment: Analyst support remains strong. BTIG Research reaffirmed a Buy rating and assigned a $14 price target, implying substantial upside from recent trading levels. Across 11 brokerages, CATX has an overall Buy consensus, with nine Buy ratings and one Strong Buy rating. Analyst rating coverage
• Positive Sentiment: Additional clinical data is gaining visibility. Perspective’s [212Pb]VMT-?-NET data were accepted for presentation at the NANETS 2026 medical symposium, providing a potential future catalyst for its neuroendocrine tumor program. VMT-?-NET data presentation announcement
• Neutral Sentiment: Institutional positioning is mixed. In the latest reported quarter, 78 institutions increased holdings while 51 reduced them. BlackRock added shares, but several other large investors exited or cut positions, suggesting continued uncertainty around CATX’s valuation and clinical outlook.
• Negative Sentiment: Insider selling and clinical risk remain concerns. Reported insiders made seven open-market sales and no purchases during the past six months. Fast Track status does not guarantee approval, efficacy or commercial success; PSV359 is still in a Phase 1/2a trial, and the company warns that trials may be delayed, fail to produce meaningful results or require additional capital.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc is a clinical-stage radiopharmaceutical biotechnology company developing precision-targeted alpha therapies for cancer. The company’s approach combines tumor-targeting molecules with radioactive isotopes to deliver highly focused radiation to cancer cells while limiting exposure to surrounding healthy tissue.

Perspective’s proprietary VMT platform is designed to support both diagnostic imaging and therapeutic applications. Its lead programs include VMT-α-NET, an investigational therapy targeting somatostatin receptor 2 for patients with neuroendocrine tumors, and VMT01, an investigational program targeting melanocortin 1 receptor-expressing cancers, including certain metastatic melanomas.